Uterine fibroids

Research output: Contribution to journalArticle

739 Citations (Scopus)

Abstract

Uterine leiomyomas (fibroids or myomas), benign tumours of the human uterus, are the single most common indication for hysterectomy. They are clinically apparent in up to 25% of women and cause significant morbidity, including prolonged or heavy menstrual bleeding, pelvic pressure or pain, and, in rare cases, reproductive dysfunction. Thus, both the economic cost and the effect on quality of life are substantial. Surgery has been the mainstay of fibroid treatment, and various minimally invasive procedures have been developed in addition to hysterectomy and abdominal myomectomy. Formation of new leiomyomas after these conservative therapies remains a substantial problem. Although medications that manipulate concentrations of steroid hormones are effective, side-effects limit long-term use. A better approach may be manipulation of the steroid-hormone environment with specific hormone antagonists. There has been little evidence-based evaluation of therapy. New research into the basic biology of these neoplasms may add new treatment options for the future as the role of growth factors and genetic mutations in these tumours are better understood.

Original languageEnglish (US)
Pages (from-to)293-298
Number of pages6
JournalLancet
Volume357
Issue number9252
DOIs
StatePublished - Jan 27 2001
Externally publishedYes

Fingerprint

Leiomyoma
Hysterectomy
Uterine Myomectomy
Steroids
Hormones
Hormone Antagonists
Neoplasms
Myoma
Uterus
Intercellular Signaling Peptides and Proteins
Therapeutics
Economics
Quality of Life
Hemorrhage
Morbidity
Pressure
Costs and Cost Analysis
Pain
Mutation
Research

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Uterine fibroids. / Stewart, Elizabeth A.

In: Lancet, Vol. 357, No. 9252, 27.01.2001, p. 293-298.

Research output: Contribution to journalArticle

Stewart, Elizabeth A. / Uterine fibroids. In: Lancet. 2001 ; Vol. 357, No. 9252. pp. 293-298.
@article{604b64c886b5411fb85783a8cb0043ea,
title = "Uterine fibroids",
abstract = "Uterine leiomyomas (fibroids or myomas), benign tumours of the human uterus, are the single most common indication for hysterectomy. They are clinically apparent in up to 25{\%} of women and cause significant morbidity, including prolonged or heavy menstrual bleeding, pelvic pressure or pain, and, in rare cases, reproductive dysfunction. Thus, both the economic cost and the effect on quality of life are substantial. Surgery has been the mainstay of fibroid treatment, and various minimally invasive procedures have been developed in addition to hysterectomy and abdominal myomectomy. Formation of new leiomyomas after these conservative therapies remains a substantial problem. Although medications that manipulate concentrations of steroid hormones are effective, side-effects limit long-term use. A better approach may be manipulation of the steroid-hormone environment with specific hormone antagonists. There has been little evidence-based evaluation of therapy. New research into the basic biology of these neoplasms may add new treatment options for the future as the role of growth factors and genetic mutations in these tumours are better understood.",
author = "Stewart, {Elizabeth A}",
year = "2001",
month = "1",
day = "27",
doi = "10.1016/S0140-6736(00)03622-9",
language = "English (US)",
volume = "357",
pages = "293--298",
journal = "The Lancet",
issn = "0140-6736",
publisher = "Elsevier Limited",
number = "9252",

}

TY - JOUR

T1 - Uterine fibroids

AU - Stewart, Elizabeth A

PY - 2001/1/27

Y1 - 2001/1/27

N2 - Uterine leiomyomas (fibroids or myomas), benign tumours of the human uterus, are the single most common indication for hysterectomy. They are clinically apparent in up to 25% of women and cause significant morbidity, including prolonged or heavy menstrual bleeding, pelvic pressure or pain, and, in rare cases, reproductive dysfunction. Thus, both the economic cost and the effect on quality of life are substantial. Surgery has been the mainstay of fibroid treatment, and various minimally invasive procedures have been developed in addition to hysterectomy and abdominal myomectomy. Formation of new leiomyomas after these conservative therapies remains a substantial problem. Although medications that manipulate concentrations of steroid hormones are effective, side-effects limit long-term use. A better approach may be manipulation of the steroid-hormone environment with specific hormone antagonists. There has been little evidence-based evaluation of therapy. New research into the basic biology of these neoplasms may add new treatment options for the future as the role of growth factors and genetic mutations in these tumours are better understood.

AB - Uterine leiomyomas (fibroids or myomas), benign tumours of the human uterus, are the single most common indication for hysterectomy. They are clinically apparent in up to 25% of women and cause significant morbidity, including prolonged or heavy menstrual bleeding, pelvic pressure or pain, and, in rare cases, reproductive dysfunction. Thus, both the economic cost and the effect on quality of life are substantial. Surgery has been the mainstay of fibroid treatment, and various minimally invasive procedures have been developed in addition to hysterectomy and abdominal myomectomy. Formation of new leiomyomas after these conservative therapies remains a substantial problem. Although medications that manipulate concentrations of steroid hormones are effective, side-effects limit long-term use. A better approach may be manipulation of the steroid-hormone environment with specific hormone antagonists. There has been little evidence-based evaluation of therapy. New research into the basic biology of these neoplasms may add new treatment options for the future as the role of growth factors and genetic mutations in these tumours are better understood.

UR - http://www.scopus.com/inward/record.url?scp=0035956680&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0035956680&partnerID=8YFLogxK

U2 - 10.1016/S0140-6736(00)03622-9

DO - 10.1016/S0140-6736(00)03622-9

M3 - Article

VL - 357

SP - 293

EP - 298

JO - The Lancet

JF - The Lancet

SN - 0140-6736

IS - 9252

ER -